Last reviewed 2026-05-14 · How we verify

JP-1366 and aspirin

Onconic Therapeutics Inc. · Phase 1 active Small molecule

JP-1366 and aspirin is a Small molecule drug developed by Onconic Therapeutics Inc.. It is currently in Phase 1 development.

At a glance

Generic name	JP-1366 and aspirin
Sponsor	Onconic Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JP-1366 and aspirin CI brief — competitive landscape report
JP-1366 and aspirin updates RSS · CI watch RSS
Onconic Therapeutics Inc. portfolio CI

Frequently asked questions about JP-1366 and aspirin

What is JP-1366 and aspirin?

JP-1366 and aspirin is a Small molecule drug developed by Onconic Therapeutics Inc..

Who makes JP-1366 and aspirin?

JP-1366 and aspirin is developed by Onconic Therapeutics Inc. (see full Onconic Therapeutics Inc. pipeline at /company/onconic-therapeutics-inc).

What development phase is JP-1366 and aspirin in?

JP-1366 and aspirin is in Phase 1.

Manufacturer: Onconic Therapeutics Inc. — full pipeline
Compare: JP-1366 and aspirin vs similar drugs
Pricing: JP-1366 and aspirin cost, discount & access